Representative End User Clients
Representative Automation Clients
Representative Software Clients
Proposed changes would streamline hub-and-spoke manufacturing registration and improve visibility into foreign pharmaceutical supply sources.
The U.S. Food and Drug Administration (FDA) has proposed a rule to modernize registration requirements for distributed drug manufacturing establishments and increase regulatory visibility into foreign sources within the pharmaceutical supply chain.
The proposed rule would establish a streamlined registration pathway for distributed manufacturing establishments operating through a hub-and-spoke model. These operations use a central hub for quality oversight and multiple equivalent manufacturing units located at different sites.
Current regulations generally require each manufacturing unit within such a network to register separately. Under the proposed rule, qualifying distributed manufacturing operations could register as a single establishment.
The proposed changes would allow manufacturers to:
Register a qualifying hub-and-spoke manufacturing network as a single establishment.
Add, relocate, or remove individual manufacturing units through a streamlined update process.
Maintain centralized quality oversight across multiple equivalent production units.
Notify the FDA before relocating a manufacturing unit.
Reduce administrative requirements associated with registering each unit separately.
The approach could make it easier for pharmaceutical companies to deploy or relocate production capacity while maintaining consistent quality management and regulatory oversight. Flexible and modular manufacturing approaches are also becoming more important as pharmaceutical companies seek to adapt production lines and facilities to changing product and capacity requirements.
ARC recently examined similar developments in Revisiting Pharma Manufacturing: Flexibility and Continuous Production, which discusses modular production systems, continuous manufacturing, automation, and the role of flexible infrastructure in creating more adaptable pharmaceutical operations.
The proposed rule would also clarify registration and drug-listing requirements for certain foreign establishments that manufacture drugs or drug components, including active pharmaceutical ingredients.
Some foreign facilities supply drugs or ingredients to other foreign establishments before those products ultimately enter the US drug supply. These upstream manufacturers may not currently be registered with the FDA, limiting the agency’s visibility into the origins of pharmaceutical products and ingredients.
The proposal would clarify that applicable foreign establishments must register with the FDA and provide information about the drugs or components they manufacture. The additional information could strengthen pharmaceutical traceability and improve the agency’s ability to identify and respond to potential quality or safety concerns.
If finalized, the rule could support greater adoption of distributed manufacturing while improving transparency across domestic and international pharmaceutical supply chains. The proposal forms part of broader FDA efforts to encourage advanced manufacturing, expand domestic pharmaceutical production, and reduce vulnerabilities within the drug supply chain.
Related ARC Insights
Pharmaceutical and Biotech Industry Poised for Investment-Driven Innovation and Growth
Accelerating Innovation and Time-to-Market in Life Sciences through AI-Powered Validation
The Hidden Complexity of Predictive Maintenance in Life Sciences
Eli Lilly Sees the Digital Plant as a Way to Accelerate Improvements
Readers can also explore ARC’s Top Technology Trends in Life Sciences and Biotech and the Advancing Life Sciences Through Digital Innovation webinar series for additional perspectives on manufacturing modernization, regulatory compliance, digital validation, and innovation across the life sciences sector.
Follow ARC Advisory Group for the latest trends in sustainability, automation, and next-generation technology.